Yana son Shi - Amma Tambayoyi Za Su Ci gaba
Wani labarin da ya bayyana a New England Journal of Medicine a ƙarshen Agusta, 2014 ya haifar da yiwuwar sabuwar nasara a cikin maganin zuciya rashin cin nasara . Wannan labarin ya fito ne daga binciken PARADIGM-HF, wanda aka yi wa marasa lafiya da ciwon zuciya zuciya tare da wani magungunan bincike. Magungunan miyagun ƙwayoyi, wanda Novartis ya fara, ya zama sabon ne wanda ba'a taba kiran shi ba - a lokacin da ake kira LCZ696.
LCZ696 a zahiri kunshi kwayoyi guda biyu sun haɗa tare - valsartan (wanda aka yi amfani da ARB mai hanawa) kuma sabon wakili, sacubitril. Sacubitril yana aiki ne ta hanyar hana kwayar cutar neprilysin , kuma sakamakon haka matakan jini na yawan peptides na haɓaka. Saboda peptides na al'ada zai iya zama da amfani a cikin hasara na zuciya, masu bincike sun ɗauka cewa LCZ696 zai iya inganta sakamakon marasa lafiya da wannan yanayin. Sakamakon binciken PARADIGM-HF ya nuna cewa masu bincike sun dace.
A cikin wannan binciken, sama da marasa lafiya 8000 tare da ciwon zuciya sun kasance bazuwar don samun ko dai LCZ696, ko farfadowa na al'ada da ke amfani da inalatril ACE . A cikin marasa lafiya da suka dauki LCZ696, bayan kimanin watanni 27 na hadarin asibiti don zuciya rashin nasara kuma hadarin mutuwa ya rage kashi 20%. Wannan matakin ingantawa, a kan abin da ake dauke da shi a halin yanzu na kirkirar zuciya, yana da kyau sosai.
Me ya sa wannan darasi yana da mahimmanci
Sakamakon PARADIGM-HF yana da muhimmanci ga akalla dalilai guda biyu. Da farko, ya nuna cewa sabon magani LCZ696 ya kamata ya ba da sabuwar bege ga marasa lafiya da yawa tare da ciwon zuciya - da zarar an yarda da shi don amfani da FDA.
Kuma na biyu, wannan binciken yana buɗe sabon hanyar da za a iya magance rashin ƙarfi na zuciya.
Saboda haka, zamu iya tsammanin ƙarin kwayoyi za a ci gaba da cewa, kamar LCZ696, ya hana inzyme neprilysin.
Yaushe Za LCZ696 Ya Kasance?
Ba za a iya ba da sababbin sababbin maganin ba har sai da FDA ta yi nazari. Da yake ganin duk yana tafiya tare da wannan bita, da farko za mu iya tsammanin zaku iya amfani da miyagun ƙwayoyi don amfani zai zama lokaci a 2015.
Shin Akwai Sakamakon Kyau tare da LCZ696?
A wannan lokacin, ana gwagwarmayar gwajin PARADIGM-HF a matsayin sabuwar nasara a cikin maganin zuciya rashin cin nasara. Kuma duk muna fatan cewa wannan ya zama batun. Duk da haka, akwai akalla dalilai uku don mu dauke da sha'awarmu a wannan lokacin.
Da farko, ana sanar da "sabuwar nasara" a duk tsawon lokacin bayan gwaji da sababbin kwayoyi. Kuma yayin da wasu lokuta yana nuna cewa nasara ta gaske ya faru, mafi yawanci yana faruwa cewa sabon magani zai iya samar da ƙarin amfani mai mahimmanci, kuma zai iya zama ƙasa da nasara, fiye da yadda ya fara.
Abu na biyu, a cikin shekaru goma da suka wuce an yi amfani da miyagun ƙwayoyi da ake kira nesiritide (Natrecor) a matsayin nasara a cikin maganin zuciya ta rashin ƙarfi. Wannan yana dacewa saboda nesiritide ba kawai ya ƙãra matakan masu peptide ba kamar yadda LCZ696 ke yi; Nesiritide wani peptide ne na natiri.
Ya ɗauki shekaru da yawa, da kuma ƙarin gwaje-gwaje na asibiti, don nuna cewa nesiritide yana da amfani kawai (idan wani) a magance rashin nasara na zuciya. Wannan tarihin ya kamata ya zama kadan daga cikin sha'awar da aka bayyana a LCZ696.
Kuma Na uku. . .
Neprilysin yana da ayyuka masu yawa banda rage matakan na peptides na natiriure, kuma wasu daga cikin waɗannan ayyuka suna da amfani. Musamman ma, neprilysin zai iya taimakawa wajen hana wasu cututtuka da suka hada da tarawar sunadaran da ba'a so a jiki, irin su cutar Alzheimer da amyloidosis , har ma da ciwon ciwon gurgu . Sabili da haka hana cikewar neprilysin bazai zama abu mai kyau na duniya ba.
Za ka iya karanta ƙarin game da wannan matsala mai matsala a nan.
- Ga wani sabuntawa a kan LCZ696 (yanzu ake kira Entresto), wadda FDA ta yarda a Yuli, 2015.
Sources:
McMurray JJV, Mista M, Desai AS, et al. Angiotensin-neprilysin hanawa zuwa enalapril a cikin zuciya rashin cin nasara. N Engl J Med 2014; DOI: 10.156 / NEJMOA1409077.
Jessup M. Neprilysin ba da izini ba - wani labari ne don rashin nasara. N Engl J Med 2014; DOI: 10.1056 / NEJMe1409898.
Nalivaeva NN, Belyaev ND, IA Zhuravin, IA, et al. Alzheimer's Amypting Peptidase, Neprilysin: Za mu iya sarrafa shi? Jaridar Duniya ta Alzheimer ta Cutar Ƙari 2012 (2012), Tambaya na ID 383796. Akwai a: http://dx.doi.org/10.1155/2012/383796 (isa ga 9/2/2014).